CMBA
SNDX icon

C.M. Bidwell & Associates’s Syndax Pharmaceuticals SNDX Stock Holding History

C.M. Bidwell & Associates’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-308
Closed -$6.47K – 519
2025
Q4 		$6.47K Hold
308
– – ﹤0.01% 300
2025
Q3 		$4.74K Buy
+308
New +$4.03K ﹤0.01% 335

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

C.M. Bidwell & Associates's SNDX Position: Q1 2026 in Review

C.M. Bidwell & Associates sold out of Syndax Pharmaceuticals (SNDX) in Q1 2026, closing a stake of 308 shares — an estimated $6.47K sold.

C.M. Bidwell & Associates first reported a position in SNDX in Q3 2025 and held it in 2 quarters. The position peaked at $6.47K in Q4 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • C.M. Bidwell & Associates reported no remaining Syndax Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 308 Syndax Pharmaceuticals shares in Q1 2026, an estimated $6.47K.
  • C.M. Bidwell & Associates first reported a position in Syndax Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Syndax Pharmaceuticals position peaked at $6.47K in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.